You should consider shares of Hologic Inc. (NASDAQ:HOLX) and CRISPR Therapeutics AG (NASDAQ:CRSP) if you are looking for a great stocks to invest in. Starting with the HOLX shares, which traded at $52.10 at the close of the recent session, dropping -1.21%. On Monday, the company’s shares shed -$0.64 from its value which represented in intraday trading. The stock is now 24.11% higher in year-to-date (YTD) trading. HOLX’s intraday high was $52.79 while its lowest price touched $52.08. The stock’s 52-week high price is $53.00, which means the current price is at -1.70%. In terms of trading activity, the daily trading volume fell to 1733963 against 200-day average trading volume of 1,827,165 shares.

What are analyst forecasts for Hologic Inc. (NASDAQ:HOLX)?

At a consensus rating of 3.83, HOLX is trending as a streaking Moderate Buy, as it has been the case a month ago when 12 analysts called it a Moderate Buy. Two months ago, 13 analysts recommended, on average, that HOLX stock is a Moderate Buy. The Healthcare company’s shares’ overall bearish trend saw it close lower on Monday compared to its opening price of $52.79 on the day.

Forecasts for Hologic Inc. (NASDAQ:HOLX) give the stock a fair value for the growth from its last price.

Hologic Inc. (NASDAQ:HOLX) Upgrades and Downgrades

In terms of rating changes, BofA/Merrill on September 26, 2019, Upgrade Hologic Inc. (HOLX) at Buy. They believe the stock could reach $59 in the near term. Analysts at Needham have assigned a Buy rating for the stock in their research note on August 01, 2019 with an estimated price target of $57. Moreover, Needham analysts issued a rating of Buy for the stock on May 02, 2019, giving it a price target of $52 for the next 12 months. On January 31, 2019, the stock earned a Buy rating due to an analyst call from Needham, while analysts from Morgan Stanley on January 02, 2019 suggested that the stock is Underweight.

CRISPR Therapeutics AG (NASDAQ:CRSP) adds -$4.92 on Monday

The CRSP stock has risen 136.09% year-to-date and is currently trading at $67.45, which is -8.85% below its 52-week high. The company shares lost -6.80% on the day and have risen nearly 203.55% off a low hit. At current levels, CRISPR Therapeutics AG has a valuation of about $212.70M. As of 12/09/19, this stock has fallen -1.71% during the week and closed at $72.37 in the previous session. However, recent CRISPR Therapeutics AG stock performance shows that CRSP shares are 37.62% up over the last month, and 46.00% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$0.78, with the trailing 12-month share earnings at -$0.46. The ratio is expected to be up by 92.70% for the current year 2019 and -1,828.00% for next year. But will the CRSP stock surprise in the current quarter results, where the $2.4 actual EPS reported on 9/29/2019 surprised by 352.60% or was higher by $3.35 from the estimated -$0.95.

Sales Growth to decline -94.30% for the year

The consensus estimated for the current quarter is $35.83M from sales. Forecasts for this fiscal year are between $212.99M and $289.3M and the consensus estimate for sales is at $250.86M.

Who owns shares in CRISPR Therapeutics AG (CRSP)?

Let’s briefly focus on the share ownership of the CRISPR Therapeutics AG (NASDAQ:CRSP) stock, where we find that 44.50% of shares are held by institutions. Versant Venture Management, LLC tops the list of institutional owners as it is holding 4.23 million shares or 7.67% of shares outstanding. ARK Investment Management, LLC and Nikko Asset Management Americas, Inc. held 2.78 million and 2.78 million representing 5.04% and 5.03% respectively at the close of the last trading session. As of Sep 29, 2019, NEA Management Company, LLC accounted for 2.09 million shares at over 85.7 million. This represented 3.79% of shares outstanding. Cormorant Asset Management, LP held 1.08 million shares at over 44.45 million representing 1.96% of shares outstanding.

CRSP Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at CRISPR Therapeutics AG (CRSP), a total of 259118 shares have been sold by insiders over the last 6 months while 264558 shares were added in the same time span. On 1/09/2019, President by the name Novak Rodger sold 82690.0 shares worth $2.9 million at the price of $35.01 per share. Filings also show that Novak Rodger sold a total of 64115.0 shares on 3/04/2019 valued at $2.6 million. Since the last insider activity, the company’s share price has climbed 81.29%.

Source link